2020 News Releases
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
LOS ANGELES, Calif., Feb. 5, 2020 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 20, 2020,
following release of its fourth quarter and full year 2019 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international).
Please dial in at least 10 minutes in advance and inform the operator that you would like to join the
“Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides
may be accessed on the Investors section of the Puma Biotechnology website
at http://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of
the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licenses the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended
adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following
adjuvant trastuzumab-based therapy and is marketed in the United States as NERLYNX® (neratinib) tablets.
NERLYNX was granted marketing authorization by the European Commission in August 2018 for the
extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-
overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant
trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
# # # # #
Back to 2020 News Releases
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024